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Purpose: To develop floating matrix tablets of salbutamol sulphate using ethyl cellulose and acrycoat S-
100 as polymers, and sodium bicarbonate, citric acid and tartaric acid as gas generating agents.  
Methods: Twenty four formulations were prepared and segregated into four major categories, A to D. 
The floating tablets were prepared by wet granulation technique, and the granules were compressed at 
a pressure of 50 kg/cm2. The tablets contained drug, ethyl cellulose and Acrycoat S-100 (as release-
retarding polymers), sodium bicarbonate, citric acid and tartaric acid (as gas formers) as well as various 
additives. The tablets were made by wet granulation technique. The formulations were evaluated for in 
vitro buoyancy, dissolution and in vitro drug release.  
Results: All the formulations fulfilled the essential requirements for good floating systems. Formulation 
F8, containing citric acid and sodium bicarbonate, showed lower lag time and longer floating duration 
than the formulations containing only sodium bicarbonate. Formulation F8.2 (which contained citric and 
tartaric acid at a ratio of 1:1) showed longer floating duration (9 h) than F8. As the concentration of 
sodium bicarbonate increased in formulation F8.2, drug release decreased while floating duration 
increased.     
Conclusion: Of all the 24 formulations, the one containing tartaric acid and citric acid in ratio 1:3 and 12 
mg sodium bicarbonate showed the highest floating duration and least lag time.   
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INTRODUCTION 
 
The high cost involved in the development of 
a new drug molecule has caused many 
pharmaceutical companies to divert greater 
attention to the development of new drug 
delivery systems. One of such delivery 
systems is gastroretentive drug delivery 
system (GDDS). Gastroretentive dosage 
formulations extend the duration of drug 
action by increasing time over which drug is 
released, thus increasing dosing intervals 
and patient compliance. Various 
gastroretentive techniques, including floating, 
swelling, high density, and bioadhesive 
systems, have been explored to increase 
gastroretention of dosage forms [1]. 
 
Floating systems are low density systems 
that have sufficient buoyancy to float over the 
gastric contents and remain in the stomach 
without affecting gastric emptying rate for a 
prolonged period. While the system floats 
over the gastric contents, the drug is released 
slowly at the desired rate, which results in 
increased gastric retentive time and reduced 
fluctuation in plasma drug concentration [2].  
The drug selected for this study, salbutamol 
sulphate, is a sympathomimetic amine used 
as a bronchodilator in the treatment of 
reversible bronchospasm. This drug is given 
in a daily dose of 4 - 8 mg and has a short 
biological half-life (1.2 h).  A GDDS 
formulation of the drug may be advantageous 
over the conventional oral dosage form and 
inhaler due to its ability to maintain prolonged 
therapeutic concentrations in systemic 
circulation [3,4]. Consequently, an attempt 
was made in the present work to develop a 
gastroretentive drug delivery system of 
salbutamol sulphate with a view to increasing 






Salbutamol sulphate, ethyl cellulose and 
Acrycoat S-100 (Corel Pharma Chem, 
Ahmedabad) were received as gifts from 
Cipla Laboratories, Himachal Pradesh, India. 
Sodium bicarbonate, citric acid (anhydrous) 
and tartaric acid were purchased from S.D. 
Fine-Chem Ltd, Ahmedabad, India. All other 
ingredients were of laboratory grade.  
 
Preparation of floating tablets  
 
All together, twenty four formulations, in four 
series (A to D), were prepared by wet 
granulation method. 
 
Formulation A series 
 
The composition of the formulations is 
mentioned in Table 1. The tablet incorporated 
the drug (salbutamol sulphate), ethyl 
cellulose and Acrycoat S-100 as matrix 
formers, and sodium bicarbonate and citric 
acid as gas generating agents. All the powder 
ingredients (talc and magnesium stearate) 
were passed through a 177 µm aperture 
sieve separately. Salbutamol sulphate, the 
polymers and diluents were mixed thoroughly 
in a glass mortar and sufficient quantity of the 
binding agent added slowly to obtain a 
dough. The mass was sieved through a 2.0 
mm mesh screen and dried on trays in a hot 
air circulation oven at 60 °C for 30 min. The 
dried granules retained on a 500 µm mesh 
were mixed with talc and magnesium 
stearate and then compressed into tablets 
using an automated single punch tabletting 
machine, keeping tablet hardness at 4 – 5 
kg/cm2 and weight at 100 ± 5 mg. 
 
Formulation B series 
 
This formulations series (F8, F8.1 and F8.2) 
was prepared to improve the floating 
capability of the best formulation in A series, 
namely, F8, by incorporating an additional 
floating agent (tartaric acid) as well as its 
combination with citric acid. The method of 
preparation was the same as for A series; the 
composition of B series is shown in Table 2. 
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Formulation C series 
 
Formulations C series (FCT1 to FCT9) was 
made to increase the floating time of the 
tablets while decreasing the disintegration 
rate. A full 32 factorial design applied on the 
best formulation of B series by taking 
reduced proportion of tartaric acid and citric 
acid to obtain the formulations. Tablet 
preparation was the same as described 
above; the composition of the series is shown 
in Table 3. 
 
Formulation D series 
 
Finally formulation design D (FCT8, FCT8.1 
and FCT8.2) was optimized by incorporating  
mixtures of citric acid and tartaric acid in 
varying ratios while retaining the sodium 
bicarbonate content in F8 of formulation C 
series. The method of preparation was as 
described earlier for A series, and the 
composition is as shown in Table 5. 
 
Full factorial design   
 
A 32 randomized full factorial design was 
used in this study.  In this design 2 factors 
were evaluated, each at 3 levels, and 
experimental trials were performed at all 9 
possible combinations.  
 
In vitro buoyancy studies  
 
In vitro buoyancy was determined by floating 
lag time and total floating time. The tablets 
were placed in a 100 ml beaker containing 
0.1M HCl. The time required for the tablet to 
rise to the surface of the liquid and the 
duration of the time it remained floating were 
noted as floating lag time and floating time, 
respectively. 
 
In vitro dissolution studies 
 
In vitro dissolution studies on the tablets were 
carried out in a USP XXIII type 2 dissolution 
test apparatus, employing a paddle stirrer at 
100 rpm in 900 ml of dissolution medium 
maintained at 37 ± 0.5 °C. The first 2 h of 
dissolution was carried out in hydrochloric 
acid buffer (HCAB, pH 1.2), followed by 5 h in 
phosphate buffer (PB, pH 6.8). At 
predetermined time intervals, 5 ml samples 
were withdrawn by means of a syringe fitted 
with a filter (0.22 µm, Raylab NZ, Ltd). The 
volume withdrawn at each interval was 
replaced with the same quantity of fresh 
dissolution medium. The samples were 
analyzed for drug release by measuring the 
absorbance at 225 nm spectrophotometrically 
(UV-1800, Shimadzu, Japan) after suitable 
dilution. All determinations were performed in 
triplicate [5-8].  
 
Analysis of kinetics of drug release  
 
To analyze the in vitro release data, various 
kinetic models, including zero order (Eq 1), 
first order (Eq 2) [9], Higuchi (Eq 3) [10], and 
Hixson-Crowell cube root law (Eq 4) [11] 
were applied to the data.  
 
C = kot      ……….…… (1)  
where, k0 is the zero-order rate constant 
expressed in units of concentration, C is 
concentration of the drug and t is time.  
 
log C = log C0 kt/2.303   .………….. (2)  
where C0 is the initial concentration of the 
drug and k is first order rate constant.  
 
Q = kt1/2    ……..…………………. (3)  
where k is a constant reflecting the design 
variables of the system and Q is cumulative 
drug release.  
 
Q01/3 -Qt1/3=KHCt   ………..………… (4)  
where Qt is the amount of drug released in 
time t, Q0 is the initial amount of drug in the 
tablet and KHC is rate constant for Hixson-
Crowell rate equation.  
 
Mechanism of drug release  
 
Two relationships, Korsemeyer–Peppas and 
Weibull models [12,13], were applied to 
determine the mechanism of drug release as 
in Eqs 5 and 6, respectively.  
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Mt/M∞ = ktn     ……………..………… (5)  
where Mt/M∞ is the fraction of drug released 
at time t, K is the rate constant and n is the 
release exponent. The value of n was used to 
determine the drug release mechanism of the 
tablets.  
 
log {-ln(1-Mt/M∞)} = blogt + log td  ………… (6) 
where Mt/M∞ is the fraction of drug released 
at the log of time, t, and b was used to 
determine the drug release mechanisms of 
the tablets. 
 
Statistical analysis  
 
Statistical evaluation was performed by 
analysis of variance (ANOVA) using Microsoft 
Office Excel 2003 and confidence limit was 
set at 95 %. Regression coefficient (R2) was 
used to determine how well a regression 
model describes the release data. Mean ± 
standard deviation (SD) for floating lag time 
and floating time were calculated using 




Formulation A series 
 
Bouyancy (floating time) data are shown in 
Table 1. Floating lag time ranged from 60 to 
80 s while duration of floating was 5 h for 
formulations F1 to F3 which contained only 
sodium bicarbonate as gas-forming agent. 
However, when sodium bicarbonate was 
combined with citric acid, the release of CO2 
increased, thus lowering floating lag time to a 
range varying from 30 to 70 s for formulations 
F4 to F9 (Table 1). Formulation F8 exhibited 
the lowest lag time (30 ± 7 s) and longest 
floating duration (8±0.5 h*) compared. 
Consequently, F8 was used for optimization 
studies. 
 
Formulation series A (F1 to F9) fitted most to 
zero order kinetics with coefficient of 
regression (R2) ranging from 0.929 to 0.985 
and 0.905 to 0.989 in HCAB and PB media, 
respectively, compared with 0.918 to 0.965 
and 0.756 to 0.966 (for Higuchi) in  HCAB 
and PB, respectively. Of all the formulations, 
F8 showed the best fit to zero order with R2 of 
0.985 and 0.989, HCAB and PB, respectively, 
and also showed the highest level of drug 
release. Hence, F8 was considered the most 
suitable for optimization study. 
 
Formulation B series 
 
Table 2 shows the results of further 
optimization of F8. It reveals that formulation 
F8.2 exhibited longer duration of floating (9 h) 
and lower lag time (20 ± 3 s) than F8.1 (6 h 
and  30 ± 5 s, respectively).  Therefore  F8.2 
 
Table 1: Composition and floating properties of formulation A series 
 
Composition (mg) Floating behavior 
Drug release 





F1 12 40 30 8 0 7 2 1 70±2 5±0.5 32.1% 42.9% 
F2 12 40 30 10 0 5 2 1 80±2 5±0.5 31.3% 23.6% 
F3 12 40 30 12 0 3 2 1 60±4 5±1.0 30.3% 45.9% 
F4 12 40 30 8 0.5 6.5 2 1 65±3 6±0.25 27.4% 41.8% 
F5 12 40 30 10 0.5 4.5 2 1 70±1 6±0.5 26.6% 41.3% 
F6 12 40 30 12 0.5 2.5 2 1 40±7 7±0.5 26.0% 43.0% 
F7 12 40 30 8 1 6 2 1 50±5 6±0.10 27.7% 42.1% 
F8 12 40 30 10 1 4 2 1 30±7 8±0.5 27.1% 49.3% 
F9 12 40 30 12 1 2 2 1 55±7 5±0.25 26.6% 41.5% 
FC = Formulation code, EC = ethyl cellulose, AS = Acrycoat S-100, SB = sodium bicarbonate, CA = citric 
acid, LA = lactose, TC = talc, MS = magnesium stearate, LT = lag time, DF = duration of floating 
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Table 2: Composition and floating properties of Formulation B series 
 
Composition (mg) Floating property 
Drug release 









F8 12 40 30 10 1 - 4 2 1 30±7 8±0.50 27.1% 49.3% 
F8.1 12 40 30 10 - 1 4 2 1 30±5 6±0.25 45.3% 48.1% 
F8.2 12 40 30 10 0.5 0.5 4 2 1 20±3 9±0.75 24.8% 54.0% 
Key: FC = Formulation code, EC = ethyl cellulose, AS = Acrycoat S-100, SB = sodium bicarbonate, CA = 
citric acid, TA = tartaric acid, LA = lactose, TC = talc, MS = magnesium stearate, LT = lag time, DF = 
duration of floating 
 
Table 3: Composition and floating properties of Formulation C series 
 


























FCT1 12 40 30 8 0.5 6.5 2 1 51±7 6.0±0.20 61.4% 
FCT2 12 40 30 8 1.0 6 2 1 40±7 7.5±0.025 65.5% 
FCT3 12 40 30 8 1.5 5.5 2 1 44±7 6.5±0.50 64.2% 
FCT4 12 40 30 10 0.5 4.5 2 1 38±4 7.5±1.00 60.5% 
FCT5 12 40 30 10 1.0 4 2 1 21± 3 10.0±1.00 81.2% 
FCT6 12 40 30 10 1.5 3.5 2 1 27± 5 8.5±0.025 82.9% 
FCT7 12 40 30 12 0.5 2.5 2 1 25±6 16.0±0.50 63.0% 
FCT8 12 40 30 12 1.0 2 2 1 22±9 18.0 ±0.50 57.9% 
FCT9 12 40 30 12 1.5 1.5 2 1 24±8 15.5±0.20 54.8% 
FC = Formulation code, EC = ethyl cellulose, AS = Acrycoat S-100, SB = sodium bicarbonate, CA = citric 
acid, TA = tartaric acid, LA = lactose, TC = talc, MS = magnesium stearate, LT = lag time, DF = duration of 
floating 
  
was selected for further optimization.  
 
All formulations in the series followed more 
closely zero order kinetics with R2 in the 
range of 0.981 to 0.991 and 0.972 to 0.981 in 
HCAB and PB media, respectively, compared 
with 0.951 to 0.962 and 0.940 to 0.954 in 
HCAB and PB, respectively, for the Higuchi 
model. F8.2 with R2 of 0.991 and 0.981 in 
HCAB and PB, respectively, showed higher 
values than the other formulations in the 
series and, therefore, was selected for further 
optimization. 
 
Formulation C series 
 
As Table 3 shows, when citric acid and 
tartaric acid were incorporated in 1:1 ratio 
while increasing the proportion of sodium 
bicarbonate in the formulation in a full 32 
factorial design, floating duration of the 
tablets increased from 6.0 ± 0.2 to 18.0 ± 0.5 
h, while lag time decreased from 51 ± 7 to 22 
± 9 s; furthermore, the  drug did not release 
rapidly from tablets not disintegrate rapidly. 
All tablets remained intact in HCAB. 
Formulation FCT8 was considered the best 
formulation on the basis of short lag time (22 
± 9 sec) and high duration of floating (18 ± 
0.5 h).  
 
When the release data for Formulations C 
series (FCT1 to FCT9) were subjected to five 
kinetic release models, the following R2 
values were obtained in HCAB media: zero 
order (0.912 to 0.998), Higuchi (0.803 to 
0.953), first order (0.942 to 0.993), Hixson-
Crowell (0.929 to 0.988) and Korsemeyer-
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Peppas (0.961 to 0.993). The R2 data fitted 
most closely to zero order kinetics, with FCT8 
(R2 = 0.998) fitting most closely of all the 
formulations in the series, hence was 
selected for further optimization.  
 
The n data obtained Korsmeyer-Peppas 
relationship suggested that all the 
formulations in the series exhibited non-
Fickian anamolous diffusion, except FCT5 
and FCT6 which followed Case II transport 
and Super Case II transport, respectively 
(Table 4). Weibull data suggest that the 
formulations followed sigmoidal release 
which is indicative of a complex drug release 
mechanism where the rate of release 
increases up to the inflection point and 
thereafter declines. Hence, FCT8 was 
selected for further optimization.       
 
Formulation D series  
 
Table 5 indicates that Formulation series D 
exhibited lag time ranging from 22 ± 9 to 18 ± 
10 s and duration of floating ranging from 
18.0 ± 0.5 to 48.0 ± 0.5 h. FCT8.2 with good 
lag time of 18±10 s and duration of floating of 
48 h was the best in the series. 
 
The Korsmeyer-Peppas n data suggest that 
FCT8 followed non-Fickian transport, i.e., 
anamolous transport while FCT8.1 and 
FCT8.2 followed Case II and super Case II 
transport, respectively. Weibull data suggest  
 
Table 4: Model fitting analysis for formulation C and D 
 
Korsmeyer-Peppas Weibull Formulation code n Diffusion mechanism b value  
FCT1 0.746 Non Fickian Anamolous 1.803 
FCT2 0.831 Non Fickian Anamolous 1.831 
FCT3 0.781 Non Fickian Anamolous 1.736 
FCT4 0.810 Non Fickian Anamolous 1.747 
FCT5 0.917 Case II Transport 1.707 
FCT6 1.052 Super Case II Transport 1.679 
FCT7 0.879 Non Fickian Anamolous 1.830 
FCT8 0.879 Non Fickian Anamolous 1.743 
FCT9 0.800 Non Fickian Anamolous 1.771 
FCT8 0.879 Non Fickian Anamolous 1.743 
FCT8.1 0.940 Case II Transport 1.832 
FCT8.2 1.028 Super Case II Transport 1.737 
The shape parameter, b, characterizes the curve as either exponential (b = 1, Case 1), sigmoid, S-shaped, 
with upward curvature followed by a turning point (b > 1, Case 2), or parabolic, with a higher initial slope 
and thereafter consistent with the exponential (b < 1, Case 3) 
 
Table 5: Composition and floating properties of formulation D series 
 





























(7 h)  
FCT8 12 40 30 12 0.5 0.5 2 2 1 22±9 18±0.5 63.0% 
FCT8.1 12 40 30 12 0.25 0.75 2 2 1 21±1 26±0.5 59.8% 
FCT8.2 12 40 30 12 0.75 0.25 2 2 1 18±1 48±0.5 65.6% 
FC = Formulation code, EC = ethyl cellulose, AS = Acrycoat S-100, SB = sodium bicarbonate, CA = citric 
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that the formulations showed sigmoidal 
release pattern which is indicative of a 
complex drug release mechanism where 
release rate increases up to the inflection 
point and thereafter declines. Therefore, 
FCT8.2 is selected as the best formulation for 




In formulation A series, sodium bicarbonate 
induced CO2 generation in the presence of 
gastric fluid. The gas generated is trapped 
within the gel formed by hydration of the 
polymer, thus decreasing the density of the 
tablet. As the density of the tablet falls below 
that of gastric fluid, the tablet became 
buoyant. 
 
The formulations containing a mixture of citric 
acid and sodium bicarbonate decreased lag 
time but increased floating duration, 
compared with  formulations containing only 
sodium bicarbonate. This could be explained 
by the fact that sodium bicarbonate present in 
the formulation as an insoluble dispersion 
becomes soluble in the acidic medium 
provided by citric acid, and released Na+ 
which reacted with the polymer and produced 
a cross-linked three-dimensional gel network 
[14]. Thus the trapped gas increases the 
duration of floating time.  
 
Moreover, strong gellation of polymer slowed 
down the rate of water diffusion into the tablet 
matrix, which resulted in the retardation of 
drug release. Additionally, citric acid 
produced a stabilizing effect on the 
formulations by forming cross-linked gel 
network in the tablets. Hence, drug release 
rate was always slower for formulations 
containing citric acid than for those without it 
(F8).   
 
Drug release from these gels was 
characterized by an initial phase of rapid 
release (burst effect). However, as gelation 
proceeds, the remaining drug was released 
at a slower rate and this feature indicates 
matrix diffusion kinetics.  
In formulation B series, the effect of an 
additional floating agent (tartaric acid) on the 
duration of floating and floating lag time of 
formulation A (F8) was studied. The result 
was that the duration of floating increased.  
 
When sodium bicarbonate reacts with citric 
acid and tartaric acid, it produces three and 
two molecules of CO2 gas, respectively [15]. 
The combination of citric acid and tartaric 
acid accelerated the changes of pH value 
inside the tablet gel compared to the 
formulation without tartaric acid, because 
tartaric acid is more soluble than citric acid. 
This favors increased production rate of CO2 
and lowers the lag time of floating but 
enhances the duration of floating time. Thus 
the floating ability of the formulation is greatly 
dependent on appropriate mixture of citric 
acid and tartaric acid. 
 
In formulation C series, increase in the 
concentration of sodium bicarbonate along 
with the incorporation of citric acid and 
tartaric acid in 1:1 ratio led to a decrease in 
drug release. This probably may be related to 
the solubility of the drug. Salbutamol sulphate 
has good solubility in aqueous solution  at pH 
7 but is sparingly to slightly soluble in alkaline 
solution. Sodium bicarbonate being alkaline 
in nature creates an alkaline 
microenvironment around the tablet and the 
drug is less soluble in alkaline pH which 
would decrease drug release from the tablet 
matrix. Formulation FCT8 was the best 
formulation on the basis of short lag time and 
high duration of floating.  
 
Interestingly, for formulation D series, the 
incorporation of citric acid and tartaric acid in 
ratio 3:1 increased floating duration to as high 
as 48 h but it also decreased drug release 
from the tablet. The mechanism underlying 





All the formulations exhibited good floating 
properties. However, incorporation of 
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appropriate ratio of citric acid and tartaric acid 
to enhance buoyancy under elevated 
stomach pH conditions caused retardation in 
drug release. Thus, by selecting a suitable 
composition of citric acid and tartaric acid 
(3:1) and sodium bicarbonate concentration 
12 mg, as in i.e. FCT8.2, the highest floating 
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